NeoGenomics (NASDAQ: NEO) reported Q2 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $66.1 million versus the consensus estimate of $62.97 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.